{"id":"07d73a75-7c11-5e74-b098-033a8a85f526","stable_key":"e054f0f5-417f-5850-a874-91ff2c9de631:sfn-apt2-membrane","predicate":"has_contextual_experimental_effect","statement":"Sulforaphane reduced the membrane-to-cytosol ratio of FLAG-tagged APT2 in HEK293 fractionation experiments.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"9c7d34f6-6161-5c8c-87a0-ea16375f26f2","mechanism_event_label":"sfn apt2 membrane","subject":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"object":{"id":"ff5a4baf-93ad-51ed-bc25-5a73e0ef0b6d","slug":"human-apt2-membrane-fraction","display_name":"Membrane-to-cytosol APT2 ratio in human cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"9c7d34f6-6161-5c8c-87a0-ea16375f26f2","stable_key":"e054f0f5-417f-5850-a874-91ff2c9de631:sfn-apt2-membrane","event_type":"experimental_result","label":"sfn apt2 membrane","description":"Sulforaphane reduced the membrane-to-cytosol ratio of FLAG-tagged APT2 in HEK293 fractionation experiments.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ff5a4baf-93ad-51ed-bc25-5a73e0ef0b6d","slug":"human-apt2-membrane-fraction","display_name":"Membrane-to-cytosol APT2 ratio in human cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2ffef5b-5457-50a8-b787-b8f24430f610","slug":"lypla2","display_name":"LYPLA2","entity_type_key":"protein"},"role":"measured protein","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_cache","value_text":"artifacts/discovery-research/round6-sources/sulforaphane-apt2.pdf; SHA256 31e2993f88fe05eec199b9013173b29379b3346b9696ac766771173ddd0f181a","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human HEK293 expressing FLAG-tagged human APT2","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"100 micromolar sulforaphane for 3 hours; membrane and cytosol fractions with pan-cadherin and alpha-tubulin markers; three separate experiments.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"These are separate experimental observations, not a demonstrated sulforaphane-GPX4-ZDHHC6 pathway. Sulforaphane-driven APT2 relocalization is not equivalent to genetic depletion or general catalytic inhibition. No dietary, clinical or selenium-repletion effect is inferred. Protein stability, palmitoylation and substrate output remain different measurements. The authors describe plasma-membrane localization, but fractionation is not an ER-specific or organelle-resolved measurement.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human experimental cells; construct species unresolved where stated for discussion-only nulls","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"Figure 4A; Results 3.4 and Methods 2.9","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1016/j.bbrc.2024.150244","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_access","value_text":"Full six-page primary PDF, methods and discussion read; Figure 4 visually inspected. No raw-data reanalysis.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"067a53b7-daf0-59a2-8732-e87e3336d953","evidence_kind":"source_excerpt","locator":"Lines 30-38","start_line":30,"end_line":38,"excerpt":"Sulforaphane reduced the membrane-to-cytosol ratio of FLAG-tagged APT2 in HEK293 fractionation experiments.\nprimary_references: https://doi.org/10.1016/j.bbrc.2024.150244\nprimary_locator: Figure 4A; Results 3.4 and Methods 2.9\nsource_access: Full six-page primary PDF, methods and discussion read; Figure 4 visually inspected. No raw-data reanalysis.\nevidence_cache: artifacts/discovery-research/round6-sources/sulforaphane-apt2.pdf; SHA256 31e2993f88fe05eec199b9013173b29379b3346b9696ac766771173ddd0f181a\nexperimental_model: Human HEK293 expressing FLAG-tagged human APT2\norganism: Human experimental cells; construct species unresolved where stated for discussion-only nulls\nexposure: 100 micromolar sulforaphane for 3 hours; membrane and cytosol fractions with pan-cadherin and alpha-tubulin markers; three separate experiments.\nlimitations: These are separate experimental observations, not a demonstrated sulforaphane-GPX4-ZDHHC6 pathway. Sulforaphane-driven APT2 relocalization is not equivalent to genetic depletion or general catalytic inhibition. No dietary, clinical or selenium-repletion effect is inferred. Protein stability, palmitoylation and substrate output remain different measurements. The authors describe plasma-membrane localization, but fractionation is not an ER-specific or organelle-resolved measurement.","model_system":"Human HEK293 expressing FLAG-tagged human APT2","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curator paraphrase and primary locator; not a verbatim publisher quote. Null-result limitations retained.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d7785cbf-e87c-5662-a76c-7ef11586cca5","stable_key":"import-e054f0f5-417f-5850-a874-91ff2c9de631","title":"APT2: sulforaphane engagement, GPX4 stability and ZDHHC6 turnover","document_type":"imported_text","citation_label":"Targeted primary-literature curation from recursive ZDHHC6 exploration, 2026-09-20.","file_path":"","sha256":"011acbeafd419a6826789806b59b5d7ff312b222762824580036325083586956","revision_id":"663a0bd1-3e46-5fee-ab0f-dcf992b2a809","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}